FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037335836> ?p ?o ?g. }

• W2037335836 endingPage "1405" @default.
• W2037335836 startingPage "1397" @default.
• W2037335836 abstract "Abstract BACKGROUND The purpose of the current study was to evaluate the effectiveness of a prostate carcinoma screening program in which serum prostate‐specific antigen (PSA) levels were measured. METHODS From a group of 20,000 men born between January 1, 1930, and December 31, 1944, 10,000 men were randomized into a screening group and 10,000 were randomized into a control group. Patients in the screening group were invited to undergo initial PSA testing between 1995 and 1996 and then were invited to receive testing every second year thereafter for 8 years (for a total of 4 PSA tests). Men with PSA levels ≥ 3 ng/mL (or ≥ 2.54 ng/mL, in the third and fourth screening rounds) were invited to undergo clinical investigation, which included sextant biopsy of the prostate. By linking to the regional cancer registry, the authors were able to obtain the true and expected incidence rates for the screening and control groups. RESULTS The screening participation rate was high (73%). A total of 884 malignancies have been detected to date, with 640 having been detected in the screening group. There was an early and marked shift toward more favorable disease stage and grade for malignancies detected on repeat screening. In the fourth screening round, only 2 of 82 detected malignancies were classified as advanced disease. Of the 227 screen‐detected tumors on which surgery was performed, only 20 (8.8%) had small volume (< 0.2 cm 3 ). Forty‐three interval malignancies were detected, but only five were accompanied by symptoms. At 8 years, the cumulative disease incidence rate among screening participants was 7.3%, compared with 2.4% in the control arm. The incidence rate observed in the screening population corresponds to the cumulative incidence rate observed in the Swedish male population at age 72 years. CONCLUSIONS Biennial PSA screening was very successful in diagnosing prostate carcinoma at an early stage, when curative treatment typically is effective. In addition, the results regarding interval malignancies were favorable. Thus, decreased mortality should be observed on long‐term follow‐up. The lead time associated with screening appears to fall within the range described in earlier studies involving frozen sera (i.e., 5–9 years). Cancer 2004;100:1397–405. © 2004 American Cancer Society." @default.
• W2037335836 created "2016-06-24" @default.
• W2037335836 creator A5022649819 @default.
• W2037335836 creator A5025140708 @default.
• W2037335836 creator A5031309091 @default.
• W2037335836 creator A5043002350 @default.
• W2037335836 creator A5056770711 @default.
• W2037335836 date "2004-03-04" @default.
• W2037335836 modified "2023-10-12" @default.
• W2037335836 title "Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma" @default.
• W2037335836 cites W1690539611 @default.
• W2037335836 cites W195741252 @default.
• W2037335836 cites W1981391870 @default.
• W2037335836 cites W1997912154 @default.
• W2037335836 cites W2001573610 @default.
• W2037335836 cites W2005865421 @default.
• W2037335836 cites W200693309 @default.
• W2037335836 cites W2008005160 @default.
• W2037335836 cites W2011802998 @default.
• W2037335836 cites W2025745367 @default.
• W2037335836 cites W2030353873 @default.
• W2037335836 cites W2031075531 @default.
• W2037335836 cites W2051834074 @default.
• W2037335836 cites W2059773982 @default.
• W2037335836 cites W2061129859 @default.
• W2037335836 cites W2065473534 @default.
• W2037335836 cites W2066965301 @default.
• W2037335836 cites W2071969245 @default.
• W2037335836 cites W2081153061 @default.
• W2037335836 cites W2088686351 @default.
• W2037335836 cites W2096252132 @default.
• W2037335836 cites W2096389968 @default.
• W2037335836 cites W2113427532 @default.
• W2037335836 cites W2332083463 @default.
• W2037335836 cites W2335679869 @default.
• W2037335836 cites W2413852552 @default.
• W2037335836 doi "https://doi.org/10.1002/cncr.20126" @default.
• W2037335836 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15042673" @default.
• W2037335836 hasPublicationYear "2004" @default.
• W2037335836 type Work @default.
• W2037335836 sameAs 2037335836 @default.
• W2037335836 citedByCount "125" @default.
• W2037335836 countsByYear W20373358362012 @default.
• W2037335836 countsByYear W20373358362013 @default.
• W2037335836 countsByYear W20373358362014 @default.
• W2037335836 countsByYear W20373358362015 @default.
• W2037335836 countsByYear W20373358362016 @default.
• W2037335836 countsByYear W20373358362017 @default.
• W2037335836 countsByYear W20373358362018 @default.
• W2037335836 countsByYear W20373358362019 @default.
• W2037335836 countsByYear W20373358362020 @default.
• W2037335836 countsByYear W20373358362021 @default.
• W2037335836 countsByYear W20373358362022 @default.
• W2037335836 countsByYear W20373358362023 @default.
• W2037335836 crossrefType "journal-article" @default.
• W2037335836 hasAuthorship W2037335836A5022649819 @default.
• W2037335836 hasAuthorship W2037335836A5025140708 @default.
• W2037335836 hasAuthorship W2037335836A5031309091 @default.
• W2037335836 hasAuthorship W2037335836A5043002350 @default.
• W2037335836 hasAuthorship W2037335836A5056770711 @default.
• W2037335836 hasConcept C120665830 @default.
• W2037335836 hasConcept C121332964 @default.
• W2037335836 hasConcept C121608353 @default.
• W2037335836 hasConcept C126322002 @default.
• W2037335836 hasConcept C126894567 @default.
• W2037335836 hasConcept C143998085 @default.
• W2037335836 hasConcept C146357865 @default.
• W2037335836 hasConcept C151730666 @default.
• W2037335836 hasConcept C168563851 @default.
• W2037335836 hasConcept C2775934546 @default.
• W2037335836 hasConcept C2775941076 @default.
• W2037335836 hasConcept C2776235491 @default.
• W2037335836 hasConcept C2777546739 @default.
• W2037335836 hasConcept C2780192828 @default.
• W2037335836 hasConcept C2781406297 @default.
• W2037335836 hasConcept C2908647359 @default.
• W2037335836 hasConcept C29456083 @default.
• W2037335836 hasConcept C61511704 @default.
• W2037335836 hasConcept C71924100 @default.
• W2037335836 hasConcept C86803240 @default.
• W2037335836 hasConcept C99454951 @default.
• W2037335836 hasConceptScore W2037335836C120665830 @default.
• W2037335836 hasConceptScore W2037335836C121332964 @default.
• W2037335836 hasConceptScore W2037335836C121608353 @default.
• W2037335836 hasConceptScore W2037335836C126322002 @default.
• W2037335836 hasConceptScore W2037335836C126894567 @default.
• W2037335836 hasConceptScore W2037335836C143998085 @default.
• W2037335836 hasConceptScore W2037335836C146357865 @default.
• W2037335836 hasConceptScore W2037335836C151730666 @default.
• W2037335836 hasConceptScore W2037335836C168563851 @default.
• W2037335836 hasConceptScore W2037335836C2775934546 @default.
• W2037335836 hasConceptScore W2037335836C2775941076 @default.
• W2037335836 hasConceptScore W2037335836C2776235491 @default.
• W2037335836 hasConceptScore W2037335836C2777546739 @default.
• W2037335836 hasConceptScore W2037335836C2780192828 @default.
• W2037335836 hasConceptScore W2037335836C2781406297 @default.
• W2037335836 hasConceptScore W2037335836C2908647359 @default.
• W2037335836 hasConceptScore W2037335836C29456083 @default.

• next